Exact Therapeutics As · OSL:EXTX
Exact Therapeutics As — Bio-Europe Spring 2024
13 slides from Exact Therapeutics As's conference presentation, Mar 18, 2024
Slide 1: EXACT Therapeutics – Bio-Europe Spring 2024
EXACT Therapeutics Bio-Europe Spring 2024 March 18, 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (the "Presentation") has been prepared by EXACT Therapeutics AS (the "Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’re
Slide 3: The ACT technology defeats biological barriers that hamper drug delivery
The ACT® technology defeats biological barriers that hamper drug delivery • Designed to provide targeted delivery of drugs to tissues throughout the body • Focus on enhancing standard of care therapies across several tumour types Standard of care therapy Microbubble Microdroplet Ultrasound PS101 i.v
Slide 4: A simple and non-invasive treatment process
A simple and non-invasive treatment process ACT achieves therapeutic benefit through a 2-step ultrasound process Step 1: Activation with high frequency (HF) Step 2: Enhancement with low frequency (LF) › › › HF ultrasound is applied Resulting in phase shift LF ultrasound is applied Oscillation of ACT
Slide 5: Strong preclinical evidence across models and drugs
Strong preclinical evidence across models and drugs Proof-of-concept Mice cancer models, combining different cancer drugs with ACT model Brain Pancreas Breast Colon Prostate Demonstrated 5x increase in ACT + therapy 4x increase in ACT + therapy targeted, complete caused the cancer to complete caused
Slide 6: ACTIVATE Phase I study – Innovative assessment of anticancer activity
ACTIVATE Phase I study – Innovative assessment of anticancer activity Insonation of one tumour Tumours Sum of diameters and volume of selected liver metastases Control Insonated Comparing % change between Baseline baseline and Week 8 for Week 8 follow up insonated vs. control lesions 6
Slide 7: Encouraging clinical evidence of anticancer activity in Phase 1 study on liver metastases
Encouraging clinical evidence of anticancer activity in Phase 1 study on liver metastases • 8 hard-to-treat patients enrolled, with a median of 5 prior lines of therapies (range 3-7) • 6 evaluable for dose limiting toxicity and tumour response • Assessment of insonated and control liver lesions at b
Slide 8: ACT for pancreatic cancer – strong preclinical data and prominent KOL support
ACT for pancreatic cancer – strong preclinical data and prominent KOL support Prof Daniel Von Hoff’s clinical trial work has led to the approval of 3 of the 4 drug combinations for treatment of pancreatic cancer patients. The ACT study by his group was done in a pancreatic cancer model in mice with
Slide 9: Next study on pancreatic cancer enabling positioning for an attractive market
Next study on pancreatic cancer enabling positioning for an attractive market Phase 2 study in first line treatment of locally advanced pancreatic cancer Vast commercial potential Demonstrated effect 64 000 new incidences* in the Demonstrated convincing responses US in 2023 and average price in huma
Slide 10: EXACT Therapeutics – a broad ACT-enabled pipeline
EXACT Therapeutics – a broad ACT-enabled pipeline Building on ACT core strengths: defeating barriers in solid tumours & providing safe BBB passage Key clinical and preclinical catalysts in 2024 • Read-out of Phase I ACTIVATE dose expansion • Opening of IND and initiation of the ENACT Phase II stud
Slide 11: International leadership team with extensive industry experience
International leadership team with extensive industry experience Anders Wold, Chairman Dr Per Walday, CEO • 40 yrs from start-up to industrial success in Ultrasound & Med • 30+ years developing pharmaceuticals from preclinical to Tech commercialization, including drug-device combinations • Former Pr
Slide 12: EXACT Therapeutics – highlights
EXACT Therapeutics – highlights Unique platform technology Attractive competitive position Ultrasound guided targeted therapeutic First mover (clinical stage) with ultrasound enhancement using proprietary micro- market leader collaboration and commercial bubbles for effective, drug agnostic delivery
Slide 13: Q&A
Q&A = ACT,